// App-Quantinova.ai

: Impact of mepolizumab on symptom severity in patients with hypereosinophilic syndrome

Researchers

Presenter

  • Florence Roufosse

Principal Investigators

  • Joseph Butterfield

  • Robyn von Maltzahn

  • Linda Nelsen

  • Jane Bentley

  • Namhee Kwon

  • Jonathan Steinfeld

Medical Centers

  • Hopital Erasme- universite Libre de Bruxelles, Brussels, Belgium

  • Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA

  • GSTT, London, UK

  • GSK, Collegeville, PA

  • GSK, Stockley Park, Uxbridge, Middlesex, UK

  • GSK, Brentford, London, UK

Locations

  • Belgium

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Genetic Disorder

Disease

  • Hypereosinophilic Syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved